Researchers led by Dr. Wang Yu at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences reported drug-inducible control of CRISPR editing in living tissues using dual small-molecule systems. In a study published in Science Translational Medicine, the team developed PRINCE and Little Prince, which switch CRISPR activity on in the presence of drug inducers and keep it largely silent without them. The work targets a core barrier to clinical deployment of genome editing: minimizing off-target effects and timing uncertainty by gating editing activity. Small-molecule control can also support dose-adjustable editing windows in tissues. For therapeutic developers, the approach extends a growing toolbox of conditional genome editing systems that aim to improve safety profiles while maintaining on-demand functionality.